Questions across 3 calls

Harshit Dhoot

Dymon Asia

Divi's Laboratories Limited

Divi's Laboratories Limited CC-Nov25.pdf · 2025-11-07

Congratulations on the great set of numbers. A couple of questions from my side. As you said, you are witnessing increasing engagement level from the clients, RFPs, site visits. So, is it fair to assume that the incremental or the higher interest of the bu siness is coming from the shift of the China?

The kind of increase in interest of the business that we are witnessing in the custom synthesis part, is it more a function of the shift of business from the China, sir? Is our innovators are diversifying from China?

IPCA Laboratories Limited

IPCA Laboratories Limited CC-Sep24.pdf · 2024-11-14

My next question is on the order expenses. We have the tender business, in which gross margin is directly still the data is a bit higher to see the way the b usiness is getting ramped out. So is it fair to assume that the 27% going forward?

No, see, sequential basis also, right, in the ForEx losses. Sir, I just w expenses going forward. So I just wanted to underst and how this operating leverage benefit will play out as we are focusing a lot on this.

Granules India Limited

Granules India Limited CC-Sep24.pdf · 2024-11-06

Hi, thanks for taking my question. My main question is on Gagillapur. Sir, given the same inspector who did the inspection of In tas and ultimately the plant got ended with import alert. So what is the -- what do you think that is giving confidence to the management for resolving this matter?

Yes, sure, sir. Sir, given the same inspector who did the inspection for the In tas and ultimately, they did import alert to the plant. So what is -- what are the things that giving confidence to the management for resolving the matter and getting the plant clear from FDA?